Objective: We evaluated whether the changes in FDG-PET/CT uptake between pre/and post-treatment might predict a complete response in esophageal cancer (EC). Patients and Methods: Fifty-six patients with 2 PET-CTs studies were evaluated retrospectively. Images were evaluated qualitatively and semiquantitatively (SUVs). Patients were classified as persistence of disease, complete metabolic response and unspecific FDG uptake. The SUVmax values and percentages of change in SUV were measured. Results: A significant difference was found between the persistence group and the non-persistence group regarding the median percentage change in SUVtumor (72.95% vs. 54.12%; p = 0.04) and regarding the percentage change in SUVnode (89.91% vs. 59.91%, p = 0.04). In patients treated with radiochemotherapy (RCTX), a significant difference was found between the persistence group and the no persistence group regarding the percentage change in SUVtumor (58.02% vs. 78.59%). Overall survival rate was related to the percentage of change in the SUVtumor. The group of ≥75% of change SUVtumor showed a median survival of 37.32 months (IC: 95% = 49.93 - 24.70) and the group of <75% of change SUVtumor showed a median survival of 18.39 months (IC: 95% = 25.14 - 11.65) (p = 0.04). In patients with metastatic relapse, a significant difference was found regarding the percentage change in SUVnode (94.63% vs. 74.09%). Conclusion: Our study provides evidence that the percentage change in the SUVmax is a predictor of the response to neoadjuvant treatment in patients with EC. When SUVmax decreases by 72.95% or more, the patient is likely a complete responder.
KeywordsPET/CTEsophagealResponseSUVPercentage
Pennathur, A., Gibson, M.K., Jobe, B.A. and Luketich, J.D. (2013) Oesophageal Carcinoma. The Lancet, 381, 400-412. https://doi.org/10.1016/S0140-6736(12)60643-6
Sjoquist, K.M., Burmeister, B.H., Smithers, B.M., et al. (2011) Survival after Neoadjuvant Chemotherapy or Chemoradiotherapy for Resectable Oesophageal Carcinoma: An Updated Meta-Analysis. The Lancet Oncology, 12, 681-692. https://doi.org/10.1016/S1470-2045(11)70142-5
Shapiro, J., van Lanschot, J.J.B., Hulshof, M., et al. (2015) Neoadjuvant Chemoradiotherapy plus Surgery versus Surgery Alone for Oesophageal or Junctional Cancer (CROSS): Long-Term Results of a Randomised Controlled Trial. The Lancet Oncology, 16, 1090-1098. https://doi.org/10.1016/S1470-2045(15)00040-6
Stahl, M., Stuschke, M., Lehmann, N., et al. (2005) Chemoradiation with and without Surgery in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus. Journal of Clinical Oncology, 23, 2310-2317. https://doi.org/10.1200/JCO.2005.00.034
Bedenne, L., Michel, P., Bouche, O., et al. (2007) Chemoradiation Followed by Surgery Compared with Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102. Journal of Clinical Oncology, 25, 1160-1168. https://doi.org/10.1200/JCO.2005.04.7118
Bruzzi, J.F., Swisher, S.G., Truong, M.T., et al. (2007) Detection of Interval Distant Metastases: Clinical Utility of Integrated CT-PET Imaging in Patients with Esophageal Carcinoma after Neoadjuvant Therapy. Cancer, 109, 125-134. https://doi.org/10.1002/cncr.22397
Monjazeb, A.M., Riedlinger, G., Aklilu, M., et al. (2010) Outcomes of Patients with Esophageal Cancer Staged with [(1)(8)F]fluorodeoxyglucose Positron Emission Tomography (FDG-PET): Can Postchemoradiotherapy FDG-PET Predict the Utility of Resection? Journal of Clinical Oncology, 28, 4714-4721. https://doi.org/10.1200/JCO.2010.30.7702
Arnett, M.K., Macintosh, E.M., James, S.E., Nathan, M.A., Shen, K.R., Ravi, K., Neben Wittich, M.A., Haddock, M.G. and Hallemeier, C.L. (2017) Utility of (18)F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma Following Chemoradiation. Journal of Thoracic Oncology, 12, 121-128. https://doi.org/10.1016/j.jtho.2016.08.136
Lordick, F., Ott, K., Krause, B.J., et al. (2007) PET to Assess Early Metabolic Response and to Guide Treatment of Adenocarcinoma of the Oesophagogastric Junction: The MUNICON Phase II Trial. The Lancet Oncology, 8, 797-805. https://doi.org/10.1016/S1470-2045(07)70244-9
Jimenez-Jimenez, E., Mateos, P., Aymar, N., et al. (2018) Radiotherapy Volume Delineation Using 18F-FDG-PET/CT Modifies Gross Node Volume in Patients with Oesophageal Cancer. Clinical and Translational Oncology, 20, 1460-1466. https://doi.org/10.1007/s12094-018-1879-3
Leong, T., Everitt, C., Yuen, K., et al. (2006) A Prospective Study to Evaluate the Impact of FDG-PET on CT-Based Radiotherapy Treatment Planning for Oesophageal Cancer. Radiotherapy & Oncology, 78, 254-261. https://doi.org/10.1016/j.radonc.2006.02.014
Matzinger, O., Gerber, E., Bernstein, Z., et al. (2009) EORTC-ROG Expert Opinion: Radiotherapy Volume and Treatment Guidelines for Neoadjuvant Radiation of Adenocarcinomas of the Gastroesophageal Junction and the Stomach. Radiotherapy & Oncology, 92, 164-175. https://doi.org/10.1016/j.radonc.2009.03.018
Mandard, A.M., Dalibard, F., Mandard, J.C., et al. (1994) Pathologic Assessment of Tumor Regression after Preoperative Chemoradiotherapy of Esophageal Carcinoma. Clinicopathologic Correlations. Cancer, 73, 2680-2686. https://doi.org/10.1002/1097-0142(19940601)73:11 3.0.CO;2-C
Jimenez-Jimenez, E., Mateos, P., Ortiz, I., et al. (2019) Nodal FDG-PET/CT Uptake Influences Outcome and Relapse Location among Esophageal Cancer Patients Submitted to Chemotherapy or Radiochemotherapy. Clinical and Translational Oncology, 21, 1159-1167. https://doi.org/10.1007/s12094-019-02038-6
Smithers, B.M., Couper, G.C., Thomas, J.M., et al. (2008) Positron Emission Tomography and Pathological Evidence of Response to Neoadjuvant Therapy in Adenocarcinoma of the Esophagus. Diseases of the Esophagus, 21, 151-158. https://doi.org/10.1111/j.1442-2050.2007.00732.x
Brucher, B.L., Weber, W., Bauer, M., et al. (2001) Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma: Response Evaluation by Positron Emission Tomography. Annals of Surgery, 233, 300-309. https://doi.org/10.1097/00000658-200103000-00002
Brucher, B.L., Swisher, S.G., Konigsrainer, A., et al. (2009) Response to Preoperative Therapy in Upper Gastrointestinal Cancers. Annals of Surgical Oncology, 16, 878-886. https://doi.org/10.1245/s10434-009-0315-x
Cremonesi, M., Garibaldi, C., Timmerman, R., et al. (2017) Interim (18)F-FDG-PET/CT during Chemo-Radiotherapy in the Management of Oesophageal Cancer Patients. A Systematic Review. Radiotherapy and Oncology, 125, 200-212. https://doi.org/10.1016/j.radonc.2017.09.022
Culverwell, A.D., Scarsbrook, A.F. and Chowdhury, F.U. (2011) False-Positive Uptake on 2-[(1)(8)F]-fluoro-2-deoxy-D-glucose (FDG) Positron-Emission Tomography/Computed Tomography (PET/CT) in Oncological Imaging. Clinical Radiology, 66, 366-382. https://doi.org/10.1016/j.crad.2010.12.004
Malik, V., Lucey, J.A., Duffy, G.J., et al. (2010) Early Repeated 18F-FDG PET Scans during Neoadjuvant Chemoradiation Fail to Predict Histopathologic Response or Survival Benefit in Adenocarcinoma of the Esophagus. Journal of Nuclear Medicine, 51, 1863-1869. https://doi.org/10.2967/jnumed.110.079566
Castoro, C., Scarpa, M., Cagol, M., et al. (2013) Complete Clinical Response after Neoadjuvant Chemoradiotherapy for Squamous Cell Cancer of the Thoracic Oesophagus: Is Surgery Always Necessary? Journal of Gastrointestinal Surgery, 17, 1375-1381. https://doi.org/10.1007/s11605-013-2269-3
Cerfolio, R.J., Bryant, A.S., Talati, A.A., et al. (2009) Change in Maximum Standardized Uptake Value on Repeat Positron Emission Tomography after Chemoradiotherapy in Patients with Esophageal Cancer Identifies Complete Responders. The Journal of Thoracic and Cardiovascular Surgery, 137, 605-609. https://doi.org/10.1016/j.jtcvs.2008.11.016
Haberkorn, U., Morr, I., Oberdorfer, F., et al. (1994) Fluorodeoxyglucose Uptake in Vitro: Aspects of Method and Effects of Treatment with Gemcitabine. Journal of Nuclear Medicine, 35, 1842-1850.
Schiepers, C., Haustermans, K., Geboes, K., et al. (1999) The Effect of Preoperative Radiation Therapy on Glucose Utilization and Cell Kinetics in Patients with Primary Rectal Carcinoma. Cancer, 85, 803-811. https://doi.org/10.1002/(SICI)1097-0142(19990215)85:4 3.0.CO;2-T
Vallbohmer, D., Holscher, A.H., Dietlein, M., et al. (2009) [18F]-Fluorodeoxyglucose-Positron Emission Tomography for the Assessment of Histopathologic Response and Prognosis after Completion of Neoadjuvant Chemoradiation in Esophageal Cancer. Annals of Surgery, 250, 888-894. https://doi.org/10.1097/SLA.0b013e3181bc9c0d